secwatch / observer
8-K filed May 8, 2026, 7:59 PM ET ticker CCEL CIK 0000862692
regulatory confidence high sentiment negative materiality 0.65

NYSE American accepts Cryo-Cell compliance plan; trading continues through Sep 2027

CRYO CELL INTERNATIONAL INC

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-214569
form_type
8-K
ticker
CCEL
cik
0000862692
company_name
CRYO CELL INTERNATIONAL INC
filed_at
2026-05-08T23:59:59+00:00
discovered_at
2026-05-14T18:02:33.832762+00:00
generated_at
2026-05-14T21:17:15.893232+00:00
sec_items
["3.01", "7.01", "9.01"]
event_type
regulatory
sentiment
negative
materiality_score
0.65
calibrated_materiality_score
0.65
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-214569
json_url
https://secwatch.observer/filing/0001193125-26-214569.json
markdown_url
https://secwatch.observer/filing/0001193125-26-214569.md
text_url
https://secwatch.observer/filing/0001193125-26-214569.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/ccel-20260506.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Source-grounded claims

129e84cf0c2c6e11a34ec716fc439494ebe4b31b

CRYO CELL INTERNATIONAL INC received a nyse_american extension granted notice regarding other.

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

SEC 8-K Item 3.01 confidence 0.75 SEC evidence

Comparable filings

GENC

Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing

GENCOR INDUSTRIES INC June 1, 2026, 4:09 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

Comparable filing

May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY

Filing page SEC filing

ATNM

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc. May 29, 2026, 5:10 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

Comparable filing

May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately

Filing page SEC filing

CDT

CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan

CDT Equity Inc. May 28, 2026, 4:30 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

Comparable filing

May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued listing on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s

Filing page SEC filing

GWAV

Greenwave receives second Nasdaq delinquency notice for late Q1 2026 10-Q filing

Greenwave Technology Solutions, Inc. May 27, 2026, 5:25 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

Comparable filing

May 21, 2026, the Company received an additional delinquency notification letter (the “Notice”) from Nasdaq due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March

Filing page SEC filing

CHAR

Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing

Charlton Aria Acquisition Corp May 27, 2026, 4:41 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

Comparable filing

May 22, 2026, Charlton Aria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that

Filing page SEC filing

BRLS

Borealis Foods receives Nasdaq deficiency notice for delayed Q1 2026 10-Q; supplements prior 2025 10-K notice

Borealis Foods Inc. May 27, 2026, 4:15 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

Comparable filing

May 21, 2026, a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, because the Company has not yet filed the Q12026 Form 10-Q, the Company no longer complies with Nasdaq Lis

Filing page SEC filing

FSHP

Flag Ship Acquisition receives second Nasdaq deficiency notice for late Q1 10-Q filing

Flag Ship Acquisition Corp May 27, 2026, 9:10 AM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

Comparable filing

May 21, 2026, Flag Ship Acquisition Corporation (the “Company”) received an additional deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) as a res

Filing page SEC filing

NVVE

Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review

Nuvve Holding Corp. May 22, 2026, 6:35 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

Comparable filing

May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-214569

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.